Advertisement
Advertisement


The Body PRO Covers: The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment

Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients

July 14, 2003


Once-daily therapies for the treatment of HIV infection have gained considerable popularity, particularly with the recent FDA-approval of the once-daily nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir (TDF, Viread) and 3TC (lamivudine, Epivir) and the once-daily protease inhibitor (PI) atazanavir (ATV, Reyataz).

The basis for the once-daily use of abacavir (ABC, Ziagen)/3TC/tenofovir stems from several previous investigations of abacavir and 3TC.1, 2 Several of these studies explored the use of twice-daily abacavir/3TC as backbones of triple-drug therapy. The maker of abacavir and 3TC, GlaxoSmithKline, has studied twice-daily abacavir/3TC backbones, demonstrating comparable performance to the standard AZT (zidovudine, Retrovir)/3TC backbone in studies with efavirenz (EFV, Sustiva) (study CNA30024).3 Other studies have shown the abacavir/3TC backbone to be compatible (dosed twice daily) with the PI nelfinavir (NFV, Viracept) or the investigational PI 908 (studies APV3001 and APV30002).4, 5 Once-daily dosing of abacavir was suggested by pharmacokinetic studies that demonstrate a long intracellular half life (study CBD-TP).6, 7

Building on the previous successes of the twice-daily Trizivir (AZT/3TC/ABC)-triple-nucleoside therapy, Farthing studied a novel, once-daily, triple-nucleoside regimen of abacavir/3TC/tenofovir. The Farthing study was a small, open-label study (meaning that patients knew what medicines they were taking) of 19 patients. It was proposed that the substitution of the potent nucleoside tenofovir for the AZT in the Trizivir-triple-nuke regimen should have resulted in increased potency and even better tolerability. The average viral load of these patients was nearly 150,000 copies/mL and their average CD4 count was 277 cells/mm3. Unfortunately, it became clear early in the study that patients taking this regimen were not doing well, as 11 of the 19 patients either had virological rebound or non-response. Nine of these 11 patients also had new drug-resistance mutations.

How do we explain these unexpected results? Firstly, any inadequate response can be thought of as a situation in which there are inadequate drug levels to suppress viral replication and hence select for drug-resistant virus. It has been established recently that the use of tenofovir unexpectedly alters the drug levels of two other antiretroviral medications. When tenofovir is used with ddI (didanosine, Videx), the level of ddI goes up, whereas with atazanavir, the level goes down. Could it be that tenofovir alters the drug level or metabolism of abacavir too?

An alternative explanation (but not mutually exclusive) is that a single amino acid substitution (mutation) in the viral reverse transcriptase can result in significant loss of potency of both abacavir and tenofovir (and to a lesser extent, 3TC) -- perhaps this unfortunate mutational coincidence makes this particular triple-drug combination more vulnerable than others to drug resistance.

Recently, a very large, randomized clinical trial (sponsored by GlaxoSmithKline) called ESS30009 reached the same conclusions about the once-daily abacavir/3TC/tenofovir-triple-nuke combination -- namely, the premature treatment failure of this regimen and the common emergence of drug resistance mutations. Very significantly, the study subjects who took the other treatment regimen, once-daily abacavir/3TC/efavirenz, have done very well, implicating that the "problem" clearly does not lie with the once-daily characteristic of the abacavir/3TC nucleoside components of the regimen, but some other yet unexplained aspect of the triple-nucleoside regimen. Details of this study have not yet been publicly presented and will be anxiously awaited.

Combined with the well publicized ACTG 5095 clinical trial results (see The Body's conference coverage for details) demonstrating the relative under-performance of Trizivir compared to two- or three-nuke combinations with efavirenz, these data should raise caution regarding the use of triple nukes alone in the treatment of therapy-naive, HIV-infected individuals. This is not to say that Trizivir has done worse than before, but rather, that the standards for treatment effectiveness have increased over time.

These studies' most important conclusion is that forecasting the effectiveness of new drug regimens can be like forecasting the weather in Colorado -- usually, but not always correct. Seemingly reasonable combinations of new drugs don't always result in the expected efficacy. It is essential to understand this point. As we get more and more drugs to treat HIV, it becomes more difficult to test all possible drug combinations. Hence, both doctors and patients alike should look for drug combinations that have good clinical trials data that distinguishes them from more speculative regimens (even ones that seem to make good sense) which don't have such rigorous scientific backing.

For another report on this study, click here.


References

  1. Bartlett J. A., Johnson J., Herrera G. et al. Abacavir/Lamivudine (ABC/3TC) in Combination With Efavirenz (NNRTI), Amprenavir/Ritonavir (PI), or Stavudine (NRTI): ESS40001 (CLASS): Preliminary 48-Week Results. Presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster 1189.

  2. Bowonwatanuwong C., Mootsikapun P., Supparatpinyo K. et al. A Randomized Open Label Study to Investigate Abacavir (ABC) and Lamivudine (3TC) as Once-Daily (QD) Components of a Triple-Combination Regimen (EPV40001). Presented at: 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; July 8-11, 2001; Buenos Aires, Argentina. Abstract 4.

  3. DeJesus E., Herrera G., Teofilo E. et al. Efficacy and Safety of Abacavir (ABC) Versus Zidovudine (ZDV) in Antiretroviral Therapy Naive Adults With HIV-1 Infection (Study CNA30024). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Poster H-446.

  4. Nadler J. P., Rodriguez-French A., Millard J. et al. The NEAT Study: GW433908 Efficacy and Safety in ART-Naive Subjects: Final 48-Week Analysis. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston, Mass. Abstract 177.

  5. Schurmann D., Gathe J., Sanne et al. Efficacy and Safety of GW433908/RTV Once Daily in Therapy Naive Subjects (The SOLO Study): 48-Week Results. Presented at: 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, United Kingdom. Late-Breaker Poster PL 14.4.

  6. Harris M., Back D., Kewn S. et al. Intracellular Carbovir Triphosphate Levels in Patients Taking Abacavir Once a Day. AIDS 2002;16(8): 1197-1198.

  7. Kewn S., Maher B., Hoggard P. G. et al. The Pharmacokinetics of Abacavir Phosphorylation in Peripheral Blood Mononuclear Cells From HIV Positive Subjects. Presented at: 5th International Congress on Drug Therapy in HIV Infection; October 22-26, 2000; Glasgow, United Kingdom. Poster 276A.

  8. Piliero P., Schachoy-Clark A. D., Para M. et al. A Study Examining the Pharmacokinetics of Abacavir and the Intracellular Carbovir Triphosphate (GSK Protocol CNA10905). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, Ill. Poster A-1797.


Previous | Next

Tell us what you think of The Body's conference coverage!


This article was provided by TheBodyPRO.com. It is a part of the publication The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.
 



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
Advertisement